Effectiveness, Safety, Adherence, and Health-related Quality of Life in HIV-1 Infected Adults Receiving Bictegravir/ Emtricitabine/Tenofovir Alafenamide (B/F/TAF) (BIC-STaR)

Gilead Sciences

Status: Completed

Conditions: HIV-1-infection

Treatments: Other: B/F/TAF

Study type: Observational

Funder types: Industry

Identifiers

NCT04009057

GS-IL-380-5335

Details and patient eligibility

About

The primary objective of this study is to evaluate HIV-1 RNA suppression, defined as HIV-1 RNA < 50 copies/mL, at 12 months after initiating or switching to bictegravir/ emtricitabine/tenofovir alafenamide (B/F/TAF).

Enrollment: 143 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• HIV-1 infection
• Signed informed consent
• Initiating treatment with B/F/TAF

Exclusion criteria

• Participation in any interventional clinical trial

Trial design

143 participants in 1 patient group

B/F/TAF

Description:

HIV-1 infected adults who initiate B/F/TAF therapy

Treatment:

Other: B/F/TAF